| HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ... Nature genetics 41 (7), 816-819, 2009 | 1179 | 2009 |
| Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale‐up in the age of direct‐acting antivirals NK Martin, P Vickerman, J Grebely, M Hellard, SJ Hutchinson, VD Lima, ... Hepatology 58 (5), 1598-1609, 2013 | 599 | 2013 |
| Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles MI Lucena, M Molokhia, Y Shen, TJ Urban, GP Aithal, RJ Andrade, ... Gastroenterology 141 (1), 338-347, 2011 | 503 | 2011 |
| Guidelines on the management of abnormal liver blood tests PN Newsome, R Cramb, SM Davison, JF Dillon, M Foulerton, EM Godfrey, ... Gut 67 (1), 6-19, 2018 | 496 | 2018 |
| Microbial biofilms in the human gastrointestinal tract S Macfarlane, JF Dillon Journal of applied microbiology 102 (5), 1187-1196, 2007 | 487 | 2007 |
| MAIT cells are activated during human viral infections B Van Wilgenburg, I Scherwitzl, EC Hutchinson, T Leng, A Kurioka, ... Nature communications 7 (1), 11653, 2016 | 485 | 2016 |
| The UK‐PBC risk scores: derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis M Carbone, SJ Sharp, S Flack, D Paximadas, K Spiess, C Adgey, ... Hepatology 63 (3), 930-950, 2016 | 380 | 2016 |
| Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis S Chowdhry, MH Nazmy, PJ Meakin, AT Dinkova-Kostova, SV Walsh, ... Free Radical Biology and Medicine 48 (2), 357-371, 2010 | 313 | 2010 |
| Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial J Grebely, O Dalgard, B Conway, EB Cunningham, P Bruggmann, ... The lancet Gastroenterology & hepatology 3 (3), 153-161, 2018 | 304 | 2018 |
| Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis RD Grose, J Nolan, JF Dillon, M Errington, WJ Hannan, IAD Bouchier, ... Journal of hepatology 22 (3), 326-332, 1995 | 261 | 1995 |
| A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices R Jalan, EH Forrest, AJ Stanley, DN Redhead, J Forbes, JF Dillon, ... Hepatology 26 (5), 1115-1122, 1997 | 245 | 1997 |
| The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations JV Lazarus, K Safreed-Harmon, MR Thursz, JF Dillon, MH El-Sayed, ... Seminars in liver disease 38 (03), 181-192, 2018 | 241 | 2018 |
| Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein … PJ Meakin, S Chowdhry, RS Sharma, FB Ashford, SV Walsh, ... Molecular and cellular biology 34 (17), 3305-3320, 2014 | 237 | 2014 |
| Oesophageal bacterial biofilm changes in gastro‐oesophageal reflux disease, Barrett's and oesophageal carcinoma: association or causality? KL Blackett, SS Siddhi, S Cleary, H Steed, MH Miller, S Macfarlane, ... Alimentary pharmacology & therapeutics 37 (11), 1084-1092, 2013 | 233 | 2013 |
| Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study P Nicoletti, GP Aithal, ES Bjornsson, RJ Andrade, A Sawle, M Arrese, ... Gastroenterology 152 (5), 1078-1089, 2017 | 224 | 2017 |
| Paracetamol toxicity: epidemiology, prevention and costs to the health‐care system CL Sheen, JF Dillon, DN Bateman, KJ Simpson, TM Macdonald Qjm 95 (9), 609-619, 2002 | 216 | 2002 |
| Microbial colonization of the upper gastrointestinal tract in patients with Barrett's esophagus S Macfarlane, E Furrie, GT Macfarlane, JF Dillon Clinical infectious diseases 45 (1), 29-38, 2007 | 192 | 2007 |
| Experimental nonalcoholic steatohepatitis and liver fibrosis are ameliorated by pharmacologic activation of Nrf2 (NF-E2 p45-related factor 2) RS Sharma, DJ Harrison, D Kisielewski, DM Cassidy, AD McNeilly, ... Cellular and molecular gastroenterology and hepatology 5 (3), 367-398, 2018 | 191 | 2018 |
| Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK R Williams, G Alexander, I Armstrong, A Baker, N Bhala, G Camps-Walsh, ... The Lancet 391 (10125), 1097-1107, 2018 | 181 | 2018 |
| Systematic review: health-state utilities in liver disease: a systematic review DJ McLernon, J Dillon, PT Donnan Medical Decision Making 28 (4), 582-592, 2008 | 177 | 2008 |
Peter HayesProfessor of Hepatology, University of Edinburgh在 ed.ac.uk 的电子邮件经过验证
